Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.

Phase 1 Dose Escalation, Single Dose Study to Assess Safety and Pharmacokinetics of BAX930 in Hereditary Thrombotic Thrombocytopenic Purpura (TTP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02216084
Recruitment Status : Completed
First Posted : August 13, 2014
Last Update Posted : October 23, 2017
Sponsor:
Information provided by (Responsible Party):
Shire ( Baxalta now part of Shire )

Tracking Information
First Submitted Date  ICMJE August 12, 2014
First Posted Date  ICMJE August 13, 2014
Last Update Posted Date October 23, 2017
Study Start Date  ICMJE September 2014
Actual Primary Completion Date February 2016   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: August 12, 2014)
Occurrence of adverse events (serious and non-serious), including the incidence of binding and inhibitory antibody formation [ Time Frame: Up to 28 (± 3) days after investigational product infusion ]
Original Primary Outcome Measures  ICMJE Same as current
Change History Complete list of historical versions of study NCT02216084 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: August 12, 2014)
  • Pharmacokinetic [PK] parameter 'incremental recovery [IR]' [ Time Frame: Within 1 hour pre-infusion and up to 288 (± 4) hours post-infusion ]
    Will be evaluated after single infusions of rADAMTS13 in Dose Cohorts 1, 2 and 3
  • PK parameter 'maximum concentration following infusion [Cmax]' [ Time Frame: Within 1 hour pre-infusion and up to 288 (± 4) hours post-infusion ]
    Will be evaluated after single infusions of rADAMTS13 in Dose Cohorts 1, 2 and 3
  • PK parameter 'minimum time to reach Cmax [T max]' [ Time Frame: Within 1 hour pre-infusion and up to 288 (± 4) hours post-infusion ]
    Will be evaluated after single infusions of rADAMTS13 in Dose Cohorts 1, 2 and 3
  • PK parameter 'terminal or disposition half-life [T1/2]' [ Time Frame: Within 1 hour pre-infusion and up to 288 (± 4) hours post-infusion ]
    Will be evaluated after single infusions of rADAMTS13 in Dose Cohorts 1, 2 and 3
  • PK parameter 'mean residence time [MRT]' [ Time Frame: Within 1 hour pre-infusion and up to 288 (± 4) hours post-infusion ]
    Will be evaluated after single infusions of rADAMTS13 in Dose Cohorts 1, 2 and 3
  • PK parameter 'systemic clearance [Cl]' [ Time Frame: Within 1 hour pre-infusion and up to 288 (± 4) hours post-infusion ]
    Will be evaluated after single infusions of rADAMTS13 in Dose Cohorts 1, 2 and 3
  • PK parameter 'area under the plasma/time curve [AUC]' [ Time Frame: Within 1 hour pre-infusion and up to 288 (± 4) hours post-infusion ]
    Will be evaluated after single infusions of rADAMTS13 in Dose Cohorts 1, 2 and 3
  • PK parameter 'steady state volume of distribution [Vss]' [ Time Frame: Within 1 hour pre-infusion and up to 288 (± 4) hours post-infusion ]
    Will be evaluated after single infusions of rADAMTS13 in Dose Cohorts 1, 2 and 3
  • Plasma von Willebrand factor: Ristocetin cofactor activity [VWF:RCo], von Willebrand factor antigen [VWF:Ag] and VWF structure analysis [ Time Frame: Within 1 hour pre-infusion and up to 288 (± 4) hours post-infusion ]
    Will be evaluated after single infusions of rADAMTS13 in Dose Cohorts 1, 2 and 3
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Phase 1 Dose Escalation, Single Dose Study to Assess Safety and Pharmacokinetics of BAX930 in Hereditary Thrombotic Thrombocytopenic Purpura (TTP)
Official Title  ICMJE BAX930 (rADAMTS13): A Phase 1 Prospective, Uncontrolled, Open-Label, Multicenter, Dose-Escalation Study Evaluating the Safety and Pharmacokinetics in Hereditary Thrombotic Thrombocytopenic Purpura (TTP)
Brief Summary The purpose of this Phase 1, prospective, uncontrolled, open-label, multicenter, dose-escalation study is to evaluate the safety, including immunogenicity, and pharmacokinetics of BAX930 (rADAMTS13) in a total of 14 evaluable subjects diagnosed with severe hereditary thrombotic thrombocytopenic purpura (TTP) (plasma ADAMTS13 activity <6%) who are assigned to one of three dose cohorts.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Hereditary Thrombotic Thrombocytopenic Purpura (TTP)
Intervention  ICMJE Drug: Recombinant ADAMTS13

rADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13) is a lyophilized formulation for intravenous injection. The lyophilized rADAMTS13 is reconstituted with sterile water for injection.

Subjects will receive an intravenous injection with rADAMTS13 at a dose of either 5 U/kg bodyweight (Cohort 1), or 20 U/kg bodyweight (Cohort 2), or 40 U/kg bodyweight (Cohort 3).

Study Arms  ICMJE Experimental: Recombinant ADAMTS13
The study is comprised of 3 dose cohorts and two dose escalation steps [Cohort 1: 3 subjects; Cohort 2: 3 subjects; Cohort 3: 8 subjects]. Subjects will be enrolled and dosed sequentially. Subjects will be recruited to the next dose level only after short-term safety has been demonstrated and reviewed by an independent Data Monitoring Committee (DMC) at the preceding dose level. The first 2 subjects in any cohort will be ≥ 18 years of age. The effects of the investigational product on vital signs, hematology, and clinical chemistry parameters (up to 96 ± 2 hrs blood sampling timepoint) will determine short-term safety. The DMC will recommend whether to proceed with the study or in case of a safety concern recommend remedial actions and/or to discontinue the study. Subject participation will continue until 28 ± 3 days after infusion of the investigational product. Subject participation in one Dose Cohort (1-3) is expected to be approximately 6-8 weeks.
Intervention: Drug: Recombinant ADAMTS13
Publications * Scully M, Knöbl P, Kentouche K, Rice L, Windyga J, Schneppenheim R, Kremer Hovinga JA, Kajiwara M, Fujimura Y, Maggiore C, Doralt J, Hibbard C, Martell L, Ewenstein B. Recombinant ADAMTS-13: first-in-human pharmacokinetics and safety in congenital thrombotic thrombocytopenic purpura. Blood. 2017 Nov 9;130(19):2055-2063. doi: 10.1182/blood-2017-06-788026. Epub 2017 Sep 14.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: February 8, 2016)
16
Original Estimated Enrollment  ICMJE
 (submitted: August 12, 2014)
14
Actual Study Completion Date  ICMJE February 2016
Actual Primary Completion Date February 2016   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Subject is between 12 and 65 years of age, inclusive. (The first 2 subjects in any cohort will be ≥ 18 years of age.)
  • Subject and/or legally authorized representative has provided written informed consent.
  • Subject has a documented diagnosis of severe hereditary ADAMTS13 deficiency, defined as 1) confirmed by genetic testing, documented in patient history or at screening, and 2) ADAMTS13 activity < 6%, documented in patient history or at screening. NOTE: In patients receiving prophylactic therapy with fresh frozen plasma (FFP) or other ADAMTS13 containing products, the levels of plasma ADAMTS13 activity may exceed 6% at screening.
  • Cryoprecipitate, FFP, or other ADAMTS13 containing products interfering with ADAMTS13 PK have to be paused at least 10 days prior to infusion of the investigational product.
  • The subject is not displaying any severe TTP symptoms at screening. Patients presenting with minor, but stable laboratory abnormalities (LDH not higher than 3 times the upper limit of normal; platelet count not lower than 100,000 per μl) at screening may be enrolled.
  • Subjects ≥18 years of age have a Karnofsky score ≥ 60%, and subjects < 18 years of age have a Lansky score ≥ 70%.
  • Subject is hepatitis C virus negative (HCV-) as confirmed by antibody or polymerase chain reaction (PCR) testing; HCV positive (HCV+) subjects are eligible for inclusion if their disease is chronic but stable.
  • If female of childbearing potential, subject presents with a negative serum pregnancy test and agrees to employ adequate birth control measures for the duration of the study.
  • Subject is willing and able to comply with the requirements of the protocol.

Exclusion Criteria:

  • Subject has been diagnosed with any other TTP-like disorder (for example, microangiopathic hemolytic anemia), including acquired TTP.
  • Subject has known hypersensitivity to hamster proteins or other components of the investigational product.
  • Subject has a medical history or presence of a functional neutralizing ADAMTS13 inhibitor at screening.
  • Subject has a medical history of immunological disorders, excluding seasonal allergic rhinitis/conjunctivitis/mild asthma, food allergies or animal allergies.
  • Subject has a medical history of hematological disorders, in particular systemic lupus erythematosus, amyloidosis, antiphospholipid antibody syndrome, vasculitis, other hemolytic anemia, disseminated intravascular coagulation, and systemic scleroderma.
  • Subject has a history of significant neurological events, such as major stroke, indicating that a relapse might have severe consequences, as judged by the investigator.
  • Subject is HIV positive with an absolute CD4 count < 200/mm3.
  • Subject has been diagnosed with a cardiovascular disease [New York Heart Association (NYHA) classes 3-4].
  • Subject is scheduled to undergo elective surgery during study participation.
  • Subject has been diagnosed with severe liver disease, as evidenced by, but not limited to, any of the following: serum ALT 3 times the upper limit of normal, international normalized ratio (INR) > 1.5, hypoalbuminemia, portal vein hypertension (e.g. presence of otherwise unexplained splenomegaly, history of esophageal varices).
  • Subject has been diagnosed with severe glomerular disease, with gross proteinuria and a serum creatinine level ≥ 2.5 mg/dL.
  • Subject has been treated with an immunomodulatory drug, in case of corticoids with an equivalent to hydrocortisone greater than 10 mg /day, excluding topical treatment (e.g. ointments, nasal spray), within 30 days prior to enrollment.
  • Subject has a history of drug and/or alcohol abuse within the last 6 months prior to study enrollment.
  • Subject has a life expectancy of less than 3 months.
  • Subject is identified by the investigator as being unable or unwilling to cooperate with study procedures.
  • Subject is a family member or employee of the investigator.
  • Subject suffers from a mental condition rendering him/her unable to understand the nature, scope and possible consequences of the study and/or evidence of an uncooperative attitude.
  • If female, subject is pregnant or lactating at the time of study enrollment.
  • Subject has participated in another clinical study involving an investigational product or device within 30 days prior to study enrollment.
  • Subject is scheduled to participate in another clinical study involving an investigational product or device during the course of this study.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 12 Years to 65 Years   (Child, Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Austria,   Germany,   Japan,   Poland,   Switzerland,   United Kingdom,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02216084
Other Study ID Numbers  ICMJE 281101
2012-003221-19 ( EudraCT Number )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Shire ( Baxalta now part of Shire )
Study Sponsor  ICMJE Baxalta now part of Shire
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director: Bruce Ewenstein, MD Shire
PRS Account Shire
Verification Date March 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP